efavirenz has been researched along with Disease Exacerbation in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (55.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bisaso, KR; Bisaso, KS; Ette, EI; Mukonzo, JK | 1 |
| Awoke Ayele, T; Kasim, A; Kebede, Y; Shkedy, Z; Worku, A; Zuma, K | 1 |
| Asano, T; Fujiki, K; Furumoto, Y; Hayakawa, Y; Horiuchi, T; Kobayashi, K; Matsumoto, T; Matsuoka, M; Misumi, Y; Miura, N; Nozaka, T; Sakamoto, N | 1 |
| Bekker, LG; Gupta-Wright, A; Lawn, SD; Wood, R | 1 |
| Holla, P; Jameel, S; Munshi, SU; Panda, H; Rewari, BB | 1 |
| Bellera, C; Ferrero, JM; Houédé, N; Ichas, F; Joly, F; Lalet, C; Laroche-Clary, A; Mourey, L; Piazza, PV; Priou, F; Puech, A; Pulido, M; Raffin, MC | 1 |
| Berendes, S; Campbell, TB; Cardoso, SW; Christian, P; Gupta, A; Gupte, N; Kanyama, C; Lama, JR; Mwelase, N; Pillay, S; Riviere, C; Samaneka, W; Semba, RD; Shivakoti, R; Sugandhavesa, P; Tang, AM; Yang, WT | 1 |
| Branco, T; Caixas, U; Germano, I; Lampreia, F; Monteiro, EC; Papoila, AL; Pereira, SA | 1 |
| Alonso-Villaverde, C; Aragonès, G; Beltrán-Debón, R; Camps, J; Fernández-Sender, L; Joven, J; Rodríguez-Sanabria, F; Rull, A | 1 |
| Beatty, G; Gruber, VA; Lum, PJ; McCance-Katz, EF; Peters, M; Rainey, PM | 1 |
| Aranda, M; Arnaiz, JA; Cortés, C; Cruceta, A; Dalmau, D; de Lazzari, E; Domingo, P; Force, L; Gatell, JM; Javaloyas, M; Knobel, H; Llibre, JM; Martínez, E; Pedrol, E; Podzamczer, D; Ribera, E; Richart, C; Riera, M; Segura, F | 1 |
| Castillo, SA; DeJesus, E; Farthing, CF; Gough, K; Grinsztejn, B; Madison, SJ; McCarty, D; Schrader, SR; Sension, MG; Shortino, DD; Thomas, DA | 1 |
| Boyd, MA; Cooper, DA; Duncombe, CJ; Lange, JM; Phanuphak, P; Ruxrungtham, K; Siangphoe, U; Stek, M | 1 |
| Antinori, A; Bongiovanni, M; Cauda, R; Ciardi, M; Cicconi, P; Cozzi-Lepri, A; De Luca, A; Di Giambenedetto, S; Grisorio, B; Marconi, P; Monforte, Ad; Resta, F; Zaccarelli, M | 1 |
| Arnaiz, JA; Dalmau, D; de Lazzari, E; Domingo, P; Force, L; Gatell, JM; Knobel, H; Leyes, M; Martínez, E; Pedrol, E; Podzamczer, D; Ribera, E | 1 |
| Calmy, A; Carey, DL; Carr, A; Cooper, DA; Emery, S; Law, MG; Samaras, K; Wand, H | 1 |
| Alvarez, E; Bellón, JM; Berenguer, J; Castillo, I; Cosín, J; López, JC; Miralles, P; Padilla, B; Resino, S; Sánchez Conde, M | 1 |
| Caro, JJ; Migliaccio-Walle, K; O'Brien, JA; Raggio, G | 1 |
| Albrecht, MA; Bosch, RJ; Dehlinger, M; Eron, J; Hammer, SM; Katzenstein, DA; Kessler, H; Liou, SH; Para, MF; Valdez, H | 1 |
| Aberg, JA; Bennett, KK; Bessen, LJ; Brosgart, C; DeGruttola, V; Eron, JJ; Gulick, RM; Hammer, SM; Holohan, MK; Karol, CN; Lewis, RH; Mellors, JW; Mitsuyasu, RT; Rogers, MD; Saah, AJ; Sheiner, L; Vaida, F; Valentine, FT; Wheat, LJ | 1 |
10 trial(s) available for efavirenz and Disease Exacerbation
| Article | Year |
|---|---|
A phase II trial evaluating the efficacy and safety of efavirenz in metastatic castration-resistant prostate cancer.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Disease Progression; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Reverse Transcriptase Inhibitors; Treatment Outcome | 2014 |
Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Body Mass Index; C-Reactive Protein; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Didanosine; Disease Progression; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Logistic Models; Male; Multivariate Analysis; Oligopeptides; Prospective Studies; Pyridines; Risk Factors; Selenium; World Health Organization; Zidovudine | 2014 |
Untreated HIV infection is associated with higher blood alcohol levels.
Topics: Adult; Alcoholism; Alkynes; Anti-HIV Agents; Benzoxazines; Cognition; Cyclopropanes; Disease Progression; Double-Blind Method; Ethanol; Female; HIV Infections; Humans; Intestinal Absorption; Male; Middle Aged; Pilot Projects; Ritonavir | 2012 |
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
Topics: Adult; Aged; Alkynes; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Disease Progression; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Failure | 2003 |
Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine | 2004 |
Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009.
Topics: Adult; Aged; Alkynes; Anthropometry; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Blood Glucose; CD4 Lymphocyte Count; Creatinine; Cyclopropanes; Disease Progression; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Indinavir; Lipids; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure; Treatment Outcome; Viral Load | 2005 |
Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Disease Progression; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nevirapine; Reverse Transcriptase Inhibitors; Treatment Outcome | 2007 |
Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection.
Topics: Adult; Alkynes; Anthropometry; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Constitution; Cardiovascular Diseases; Cyclopropanes; Diabetes Mellitus, Type 2; Disease Progression; Epidemiologic Methods; Female; HIV Infections; Humans; Male; Metabolic Syndrome; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors | 2007 |
Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
Topics: Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Male; Mutation; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral; Treatment Failure; Viral Load | 2001 |
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Disease Progression; Double-Blind Method; Drug Resistance, Viral; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Organophosphonates; Oxazines; Proportional Hazards Models; Reverse Transcriptase Inhibitors; Saquinavir; Sulfonamides; Treatment Failure; Viral Load | 2002 |
10 other study(ies) available for efavirenz and Disease Exacerbation
| Article | Year |
|---|---|
Maximizing Knowledge Extraction From Patient-Reported Outcome Data Using Exposure-Outcome Item Response Modeling Approach: Understanding Efavirenz-Induced Central Nervous System Toxicity.
Topics: Alkynes; Benzoxazines; Central Nervous System; Cognitive Dysfunction; Computer Simulation; Cyclopropanes; Disease Progression; Drug Administration Schedule; Hallucinations; HIV Infections; Humans; Models, Psychological; Patient Reported Outcome Measures; Patient-Specific Modeling; Reverse Transcriptase Inhibitors; Severity of Illness Index; Sleep Wake Disorders; Symptom Assessment; Time Factors | 2020 |
Model-based prediction of CD4 cells counts in HIV-infected adults on antiretroviral therapy in Northwest Ethiopia: A flexible mixed effects approach.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Disease Progression; Ethiopia; HIV Infections; Humans; Models, Biological; Retrospective Studies | 2019 |
A case of esophageal cancer with human immunodeficiency virus infection that progressed rapidly after neoadjuvant chemoradiotherapy.
Topics: Aged; Alkynes; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoxazines; Chemoradiotherapy; Cisplatin; Cyclopropanes; Deglutition Disorders; Disease Progression; Drug Interactions; Emtricitabine; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fatal Outcome; Female; Fluorouracil; Gastrostomy; HIV Infections; Humans; Neoadjuvant Therapy; Neoplasm Staging; Renal Insufficiency; RNA, Viral; Tenofovir; Viral Load | 2020 |
Temporal association between incident tuberculosis and poor virological outcomes in a South African antiretroviral treatment service.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Incidence; Lamivudine; Male; Medication Adherence; Nevirapine; Risk Factors; South Africa; Stavudine; Time Factors; Tuberculosis; Viral Load | 2013 |
MicroRNA-150 is a potential biomarker of HIV/AIDS disease progression and therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; CD4 Lymphocyte Count; Cyclopropanes; Disease Progression; Drug Resistance, Viral; Female; Gene Expression Regulation; HIV; Humans; Lamivudine; Leukocytes, Mononuclear; Male; MicroRNAs; Nevirapine; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2014 |
Efavirenz concentrations in HIV-infected patients with and without viral hepatitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Benzoxazines; Case-Control Studies; CD4 Lymphocyte Count; Cyclopropanes; Disease Progression; Dose-Response Relationship, Drug; Drug Monitoring; Female; Follow-Up Studies; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Liver Diseases; Male; Pilot Projects; Reverse Transcriptase Inhibitors; Severity of Illness Index; Treatment Outcome; Viral Load | 2008 |
Human immunodeficiency virus-infection induces major changes in high-density lipoprotein particle size distribution and composition: the effect of antiretroviral treatment and disease severity.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4-Positive T-Lymphocytes; Chromatography, Gel; Cyclopropanes; Disease Progression; Female; HIV Infections; Humans; Lipoproteins, HDL; Male; Middle Aged; Particle Size | 2010 |
Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
Topics: Adult; Aged; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hypertriglyceridemia; Italy; Lopinavir; Male; Middle Aged; Nucleosides; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure; Viral Load | 2006 |
Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Disease Progression; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Nevirapine; Protease Inhibitors; Retrospective Studies; Reverse Transcriptase Inhibitors; Ribavirin; Viral Load | 2008 |
Economic analysis of initial HIV treatment. Efavirenz- versus indinavir-containing triple therapy.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Disease Progression; Drug Costs; Drug Therapy, Combination; Health Care Costs; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Models, Economic; Oxazines; Reverse Transcriptase Inhibitors | 2001 |